Member Info for BetterX

The major negative on the SP is Woodford. He will be almost certainly lowering his stake due to FCA requiring liquidity to cover withdrawals and knowledge that he will be doing so will be causing uncertainty & delay for those looking to invest. So its a double Woodford whammy currently which is making this share continue to trade at bargain basement levels. Should be some relief on run up to XD date 15th August & the low price should attract II's.

Your comments will resonate with many others as we are all wiser in retrospect. The results are v good & underpin the move north in the SP. The DoJ action is the only issue stopping the SP being well, well north of £1. I would not be short of this stock because positive DoJ news can hit at any time.

Timing is key & no-one can be blamed for taking profits when available although a sharp rise in SP after doing so can take the gloss off the gain & make it feel like a loss. The market cap currently is about £400m whilst cash alone at Q1 was about £650m. Obviously the DoJ issue is still unresolved but trading is better than expected even given generic competition. The opioid epidemic is not going away anytime soon and SUBLOCADE is doing well. New medication PERSERIS will continue to make progress helped by cannabis legalisation. The current SP does not at all reflect the true value of INDV even given the DoJ issue. Any positive update on the DoJ tomorrow will put the SP into orbit. But a further positive trading update without DoJ news will still underpin SP & continue share trend North. Buy on dips, DYOR, all comments IMHO.

This seriously under-valued stock is beginning to make progress today but still has a long way to go to reflect its true value. Results due next week will act as a catalyst.

A great opportunity to buy more on the dips.

A mix of today's legal news and half year results out next week. Anyone on a short position on this share at the moment must be on opioids.

Year high for the stock is £3.35. It has fallen due to combined effect of 2 major issues, the DoJ case & concern over generics taking market share & acting to depress margins. A third concern is over-reliance on opioid dependency products. Recent events have shown all 3 concerns to be over-hyped. DoJ have agreed a settlement with Reckitt's (former INDV owner) which suggests that a settlement with INDV is in the offing although a lot of debate about the size of any payment that may need to be made. INDV's recent trading statement has indicated that loss of market share & margin is much less than had been feared & user comments suggest that the INDV products are preferred to Dr Reddy generic. INDV have also recently made progress with their new schizophrenia drug PERSERIS which indicates that they are looking to extend their portfolio of products outside opioid dependency. INDV is not without risk but at current SP it is IMHO a bargain with significant upside. DYOR etc

Compelling investment opportunity IMHO, I have large investment in INDV & believe that the SP will greatly increase over the coming weeks. Obviously DYOR

The below news would also have helped sentiment:
"Neil Woodford plans to start offloading stakes in illiquid biotech investments from the end of this month as he seeks to save his £3.7 billion suspended fund. Link Fund Solutions, the authorised corporate director of the Woodford Equity Income Fund, has lined up PJT, the boutique investment bank, to start the sale process. – The Times" If Woodford starts selling the illiquid parts of his funds it will take pressure off his need to sell his quoted investments.

That's the problem, he can't sell the non-quoted quickly & is having to sell the quoted shares. He's under time pressure from the FCA to have cash available to be able to pay out the investors wanting to exit his funds. Given that he once owned 20+% of PFG (probably down to mid-teens now) its a massive negative on the SP.

Ongoing Woodford effect weighing on the SP. Great opportunity to buy at bargain basement price. DYOR

I can only repeat what I have stated before that INDV is a screaming buy. I have taken the opportunity to add to my holding at these v low prices & so thank the shorters who keep driving the price down. There will (IMHO) be a RNS sooner rather than later on the DoJ action which will already be virtually a done deal for many of the reasons already stated by others. Once that is out of the way the SP will rocket. The INDV product also appears to be the preferred product by users which bolsters the forward trading forecasts. I also believe that once DoJ put to bed the stock becomes v attractive to a predator at any SP under GB£1.50. DYOR etc

Given that DRL has been found not to infringe INDV's patents then this must mean that the DRL product is different to INDV's. This could help to explain why users are finding INDV's original product preferable to DRL's "copy".

One thing that may have been missed which is very important is the following snippet from yesterday's first RNS. "and we are continuing to see early interest in PERSERIS™." One of the negatives that financial commentators like Motley Fool have leveled at INDV is that they are essentially a 1-trick pony with opioid addiction being their main focus. Traction with PERSERIS therefore shows that they are capable of developing a wider stable of commercially important medications. Given the wide legalisation of cannabis use in N America this particular drug (unfortunately) will be in great demand.

It is a perverse reaction but herd instinct kicks in & the second RNS spooked the herd. Momentum took down to the low point this am before calm appraisal of the situation returned. Still massively under-priced IMHO.

It must be excruciating for Woodford having to sell at these v low prices. He is not master of his own destiny any more and will have to get enough cash together to satisfy FCA that in a position to pay out substantial withdrawals that will surely come in due course. So every other PFG investor (myself included) & potential investors are waiting to see how low this can go before buying more. Make no mistake at this price the shares are IMHO a total & absolute steal but if 10 or 15 or 20p cheaper is on the horizon then might as well wait. The only risk to this waiting strategy is that at this bargain basement price Woodford's stake is bought by a LTH and the SP goes through the roof as everyone else jumps on board.

RBTrader, I do not believe that RB's legal team have been working independently of INDV's legal team. This will not be a bolt from the blue for them. So this begs the question of exactly when a RNS relating to the DoJ case will be released by INDV and obviously the content of it. Clarification on this issue is required.

RBTrader, the Reuters release does suggest that this relates to the whole matter. It would be helpful to get an RNS from INDV specifically relating to this issue clarifying the situation & how much (if anything) that INDV has had to pay into the pot.

It is not crystal clear at the moment. Read the RNS part referring to "to fully resolve all federal investigations into RB...".

The trading update itself is massively important even without the DoJ news. But the DoJ news shows that it was always about how much they could screw out of RB for them to get a settlement. If (this being the operative word) INDV needs to pay DoJ also then should be well within their provision. It also removes the uncertainty that the DoJ would take to trial. DoJ only interested in extracting a fine. Once full ramifications of todays news sinks in (based on my take of events) then I repeat SP will be well north of £1. Obviously DYOR.